A progressive liver condition affects thousands of Americans, but early symptoms are often dismissed as everyday ailments. Learn the critical warning signs of Primary biliary cholangitis (PBC) and ...

The global prevalence of primary biliary cholangitis (PBC) has increased, particularly in the Western Pacific region of the world, according to study results published in Clinical Gastroenterology and ...

GSK's marketing application for linerixibat, targeting cholestatic pruritus in PBC patients, gains EMA acceptance based on phase III success.

EMA accepts GSK’s MAA for linerixibat for cholestatic pruritus in patients with primary biliary cholangitis: London, UK Tuesday, June 24, 2025, 09:00 Hrs [IST] GSK plc announced ...

Similar to clinical outcomes in primary biliary cholangitis (PBC), recent data from retrospective studies support the use of falling ALP (normalisation or <1.5 x upper limit of normal (ULN)) as a ...

The EMA has started a review of GSK's treatment candidate for primary biliary cholangitis (PBC), linerixibat, offering hope ...

GSK said on Monday that the European Medicines Agency has accepted its marketing authorisation application for linerixibat, an investigational treatment for cholestatic pruritus in patients with ...

Objective The aetiology of primary biliary cirrhosis (PBC) is largely unknown. Previous studies have indicated that both environmental and genetic risk factors may be important. Design We undertook a ...